{
    "medicine_id": "355134e9a9b615df759c36f7c980512e1b543e66",
    "platform_id": "DB06766",
    "metadata": {
        "name": "Lastacaft 2 5 mg 1mL Solution",
        "composition": "2 5 mg 1mL Alcaftadine",
        "clinical_particulars": {
            "therapeutic_indications": "For the prevention of itching associated with allergic conjunctivitis",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Following bilateral topical ocular administration of alcaftadine ophthalmic solution 0 25 the mean plasma Cmax of alcaftadine was approximately 60 pg mL and the median Tmax occurred at 15 minutes Plasma concentrations of alcaftadine were below the lower limit of quantification 10 pg mL by 3 hours after dosing The mean Cmax of the active carboxylic acid metabolite was approximately 3 ng mL and occurred at 1 hour after dosing Plasma concentrations of the carboxylic acid metabolite were below the lower limit of quantification 100 pg mL by 12 hours after dosing",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB00656",
                        "description": "The risk or severity of QTc prolongation can be increased when Trazodone is combined with Alcaftadine"
                    },
                    {
                        "drugbank-id": "DB11642",
                        "description": "Alcaftadine may increase the QTc prolonging activities of Pitolisant"
                    },
                    {
                        "drugbank-id": "DB12825",
                        "description": "Lefamulin may increase the QTc prolonging activities of Alcaftadine"
                    },
                    {
                        "drugbank-id": "DB00557",
                        "description": "The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Hydroxyzine"
                    },
                    {
                        "drugbank-id": "DB00246",
                        "description": "The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Ziprasidone"
                    },
                    {
                        "drugbank-id": "DB00502",
                        "description": "The risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Haloperidol"
                    },
                    {
                        "drugbank-id": "DB00472",
                        "description": "The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Alcaftadine"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}